Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* respiratory rate \> 30 bpm at admission;
* ratio of PaO2 to fraction of inspired oxygen (PaO2:FIO2 ) \< 250;
* chest radiograph showing bilateral involvement or multilobar involvement;
* systolic blood pressure \< 90 mm Hg; or
* diastolic blood pressure \< 60 mm Hg. Major criteria includes
* Requirement of MV;
* Increase in the size of opacities on chest radiograph of 50% or more at 48 hours;
* Requirement of vasopressors for more than 4 hours; or
* Serum creatinine 2 mg/dl or more.
Exclusion criteria:
* Children;
* Nosocomial pneumonia;
* Hospitalisation within the previous 14 days;
* Severe immunosuppression (chronic use of systemic steroids);
* Non-steroid immunosuppressive treatment or HIV);
* Chronic chest disease; , tuberculosis, aspiration or obstructive pneumonia;
* Congestive heart failure (cerebrovascular stroke);
* Chronic renal or hepatic disease;
* Acute burn injury;
* Malignancy;
* Pregnancy; and
* Major gastrointestinal bleed within 3 months of the current hospitalization
Study Outcome The end-points of the study were improvement in PaO2:FIO2 (PaO2:FIO2 \> 300 or ≥100 increase from study entry) and sepsis related organ failure assessment, (SOFA) score by day 8 and the development of delayed septic shock.
The adopted SOFA score (up to 6 points) was proposed by Vincent et al., \[21\]. The number of MV-free days was defined as the number of days after ventilation was discontinued up to study day 8. Shock was defined as requirement of vasopressors. ARDS was defined by consensus criteria.
All the patients were subjected to
1. Routine laboratory screen, including CBC, RBS, serum urea and creatinine, liver enzymes, serum billirubin and coagulation profiles;
2. Chest X ray on at least on admission and at day 8;
3. ABG at least once daily to detect PaO2:FIO2;
4. CRP daily from day 1 to 8 and
5. Evaluation of SOFA score daily
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Corticosteroid group
This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
Hydrocortison
Placebo group
This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
Saline Solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydrocortison
Saline Solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* respiratory rate \> 30 bpm at admission;
* ratio of PaO2 to fraction of inspired oxygen (PaO2:FIO2 ) \< 250;
* chest radiograph showing bilateral involvement or multilobar involvement;
* systolic blood pressure \< 90 mm Hg; or
* diastolic blood pressure \< 60 mm Hg. Major criteria included
* Requirement of MV;
* Increase in the size of opacities on chest radiograph of 50% or more at 48 hours;
* Requirement of vasopressors for more than 4 hours; or
* Serum creatinine 2 mg/dl or more. 10
Exclusion Criteria
* Nosocomial pneumonia;
* Hospitalisation within the previous 14 days;
* Severe immunosuppression (chronic use of systemic steroids);
* Non-steroid immunosuppressive treatment or HIV);
* Chronic chest disease; , tuberculosis, aspiration or obstructive pneumonia;
* Congestive heart failure (cerebrovascular stroke);
* Chronic renal or hepatic disease;
* Acute burn injury;
* Malignancy;
* Pregnancy; and
* Major gastrointestinal bleed within 3 months of the current hospitalization.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cairo University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06111972
Identifier Type: -
Identifier Source: org_study_id